JTP 2942
JTP 2942 is a thyrotropin-releasing hormone analogue. JTP 2942 can promote the release of Acetylcholine in the hippocampus and frontal cortex of rats. JTP 2942 possesses neuroprotective and cognitive-improving activities. JTP 2942 dose-dependently improves motor and neurological deficits in rat models of chronic focal cerebral ischemia. JTP 2942 can be used for the research of cerebral ischemia, motor neuron diseases, and other related conditions.
For research use only. We do not sell to patients.
- CAS No.: 148152-77-6
- Formula: C18H25N5O4
- Molecular Weight:375.42
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Description
Chemical Information
-
CAS No. 148152-77-6
-
Molecular Weight 375.42
-
Formula C18H25N5O4
-
SMILES
O=C([C@@H]1[C@@H](CC(C1)=O)C)N[C@@H](CC2=CN=CN2)C(N3[C@@H](CCC3)C(N)=O)=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
Purity & Documentation
References
[1]. Yonemori F, et al. Effect of JTP-2942, a novel thyrotropin-releasing hormone analog, on motor deficits after chronic focal cerebral ischemia in rats. J Cereb Blood Flow Metab. 2000 Jan;20(1):74-81. [Content Brief]
[2]. Ikeda K, et al. JTP-2942, a novel thyrotropin-releasing hormone analogue, protects against spinal motor neuron degeneration in the wobbler mouse. Neurosci Lett. 1998 Jun 26;250(1):9-12. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
JTP 2942 Related Classifications
HY-119495 Related Classifications
Powered by Bioz